Skip to content

Effects of Different Types of Exercise on Irisin and Cognitive Performance (Exercise-Irisin)

Effects of Exercise Intensity on Neurochemical and Cognitive Function: The Role of Lactate and Irisin

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07146490
Acronym
Ex-Irisin
Enrollment
12
Registered
2025-08-28
Start date
2025-06-10
Completion date
2025-08-05
Last updated
2025-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irisin, Lactate, Cognitive Function, Exercise Training

Keywords

HIIT, Irisin, Lactate, Cognitive Function

Brief summary

Purpose The purpose of this study was to determine the acute effects of different exercise intensities on Irisin levels, trail making test performance, and feeling scale. Method This randomized crossover controlled trial aims to examine the acute effects of three experimental conditions-Short-Interval High-Intensity Interval Training (SI-HIIT), Long-Interval High-Intensity Interval Training (LI-HIIT) and Low-Intensity Continuous Training (LICT), on cognitive performance (via the Trial Making Test, ) and associated neurochemical responses (e.g., serum Irisin and blood lactate levels) in healthy young adults aged 18-25 years. All participants completed the three conditions in a randomized and counterbalanced manner. To ensure balanced exposure, they were assigned to one of three groups (n = 4 per group), each following a distinct condition order based on a Latin square design. This approach guaranteed that each session occurred equally across time points (sessions 1-3) and that the order minimized sequence effects by rotating the position of each condition relative to the others. To control for potential carryover-particularly from elevated neurochemical responses following intense exercise (Irisin increases reported -no two high-intensity sessions were scheduled consecutively. Where possible, higher and lower intensity protocols were be alternated. Furthermore, a seven-day interval separated each session to reduce residual physiological or cognitive effects. The trial protocol was developed in line with CONSORT and SPIRIT guidelines, including relevant extensions for within-subject designs and non-pharmacological interventions. Participants were blinded to the study hypothesis. All exercise sessions conducted under supervision of a certified strength and conditioning coach to ensure consistency and adherence to protocol in the morning (09:00-11:00) on a track and field pitch to control for chronobiological variation. Participants were instructed to avoid strenuous activity for 48 hours prior, abstain from alcohol and caffeine for 24 hours, and obtain at least 7-8 hours of sleep before each session. Dietary habits and general lifestyle were to remain unchanged throughout the study. During the first visit, participants' body weight and body fat percentage were assessed using bioelectrical impedance analysis. Resting heart rate was then recorded, followed by administration of the Yo-Yo Intermittent Recovery Test Level 1 to determine maximal aerobic speed, aerobic capacity, and peak heart rate. In the following four visits, each participant completed all experimental conditions. Each exercise session began with a standardized 10-minute warm-up, including light jogging, dynamic stretching, and movement preparation drills. All exercise sessions were conducted on a standard track and field facility and lasted 40 minutes in total, consisting of a 10-minute standardized warm-up, 24 minutes of exercise, and a 5-minute recovery period. The exercise component was individually prescribed based on each participant's maximal aerobic speed, determined from the Yo-Yo Intermittent Recovery Test Level 1. All running distances were calculated individually using time × speed formulas based on each participant's maximal aerobic speed, ensuring workload equivalence across conditions. * Short-interval high-Intensity Interval Training: Participants ran at 110-120% of their MAS for 15-second intervals. * Long-interval high-Intensity Interval Training: Participants ran at a speed corresponding to 80-90% of their MAS. * Low-Intensity Continuous Training: Participants ran continuously for 24 minutes at 50-60% of their MAS without breaks. Venous blood samples were collected before and immediately after each session to assess neurochemical markers. Subsequently, cognitive performance was evaluated using the computerized Trial Making Test to measure executive function. Heart rate was continuously monitored during all exercise conditions using a Polar V800 device. Following each session, psychophysiological responses were assessed using the Feeling Scale.

Interventions

BEHAVIORALLow Exercise

Low-Intensity Continuous Training (LICT): Participants ran continuously for 24 minutes at 50-60% of their MAS without breaks.

BEHAVIORALLong Interval Exercise

Long-interval high-Intensity Interval Training (LI-HIIT): Participants ran at a speed corresponding to 80-90% of their MAS. The protocol consisted of four 4-minute bouts, separated by 2-minute active recovery periods, during which participants ran at 50% of their MAS. This pattern totaled 24 minutes of exercise.

BEHAVIORALShort Intevral Exercise

Short-interval high-Intensity Interval Training (SI-HIIT): Participants ran at 110-120% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they rested passively for 15 seconds and returned to their starting point. This was repeated continuously for 3 minutes, constituting one set. A total of four 3-minute sets were completed, interspersed with 3-minute passive rest periods, yielding a total exercise time of 24 minutes.

Sponsors

Aksaray University Training and Research Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged between 18 and 25 years * No known medical condition that prevents participation in exercise * Not currently using any pharmacological agents

Exclusion criteria

* Experiencing any discomfort before, during, or after exercise * Current or past diagnosis of pharmacological or doping substance use * Engaging in regular exercise (more than 3 times per week) within the last 2 weeks * History of alcohol or substance addiction * Any other condition or factor that may prevent full participation in the study protocol

Design outcomes

Primary

MeasureTime frameDescription
LactateBaseline and immediately after exercise (Day 1)Lactate levels were measured in millimoles per liter (mmol/L) from capillary/venous blood samples taken before and after exercise using a lactate analyzer.
IrisinBaseline and immediately after exercise (Day 1)Irisin levels were measured using a Sunred brand ELISA kit from blood samples taken baseline and after exercise, and the results were reported in pg/mL units.
Trial Making TestBaseline and immediately after exercise (Day 1)The Trail Making Test (TMT) is a widely used neuropsychological assessment tool to evaluate attention, visual scanning, processing speed, mental flexibility, and executive function. TMT-A measures processing speed and visual attention by requiring participants to connect sequential numbers (1-25) as quickly as possible. Completion times were recorded in seconds. TMT-B measures cognitive flexibility and executive control by requiring participants to alternate between numbers and letters (1-A-2-B, etc.).
Feeling ScaleBaseline and immediately after exercise (Day 1)The Feeling Scale (FS) is a single-item measure of affective valence during or after exercise. Participants are asked, How are you feeling right now? and respond on an 11-point bipolar scale ranging from -5 to +5. Scoring: -5 = Very Bad 0 = Neutral +5 = Very Good Negative scores indicate unpleasant affect, whereas positive scores indicate pleasant affect. Higher scores reflect better subjective feelings.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026